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NOD-like receptor (NLR) proteins are intracellular
innate immune sensors/receptors that regulate im-
munity. This work shows that NLRX1 serves as a tu-
mor suppressor in colitis-associated cancer (CAC)
and sporadic colon cancer by keeping key tumor
promoting pathways in check. Nlrx1/ mice were
highly susceptible to CAC, showing increases in
key cancer-promoting pathways including nuclear
factor kB (NF-kB), mitogen-activated protein kinase
(MAPK), signal transducer and activator of transcrip-
tion 3 (STAT3), and interleukin 6 (IL-6). The tumor-
suppressive function of NLRX1 originated primarily
from the non-hematopoietic compartment. This
prompted an analysis of NLRX1 function in the
Apcmin/+ genetic model of sporadic gastrointestinal
cancer. NLRX1 attenuatedApcmin/+ colon tumorigen-
esis, cellular proliferation, NF-kB,MAPK, STAT3 acti-
vation, and IL-6 levels. Application of anti-interleukin
6 receptor (IL6R) antibody therapy reduced tumor
burden, increased survival, and reduced STAT3
activation in Nlrx1/Apcmin/+ mice. As an important
clinical correlate, human colon cancer samples ex-
pressed lower levels of NLRX1 than healthy controls
inmultiple patient cohorts. These data implicate anti-
IL6R as a potential personalized therapy for colon
cancers with reduced NLRX1.INTRODUCTION
Members of the nucleotide binding domain and leucine-rich
repeat-containing (NLR, also known asNOD-like receptor) family2562 Cell Reports 14, 2562–2575, March 22, 2016 ª2016 The Authorare evolutionarily conserved components of the immune system
that are key mediators of immune defense and inflammation
(Takeuchi and Akira, 2010). The major focus in the NLR field is
on the inflammasome NLRs, which activate caspase-1 resulting
in production of interleukin 1b (IL-1b) and interleukin 18 (IL-18).
A subgroup of NLRs play an important role in the regulation of
signaling pathways crucial for cell proliferation, survival, cellular
differentiation, adhesion, migration, and metabolism, such as
mitogen-activated protein kinases (MAPK) and nuclear factor kB
(NF-kB) (Hayden and Ghosh, 2011; Sebolt-Leopold and Herrera,
2004; Wullaert et al., 2011). Aberrant activation of these path-
ways initiate and promote tumor development (Elinav et al.,
2013); thus, it is important to determine if NLRs control these
pathways during tumorigenesis and if these findings have trans-
lational relevance in human cancers.
Colorectal cancer (CRC) is the third most common cancer in
both men and women and the second leading cause of cancer-
related mortality in the United States with estimates of over
130,000 new cases diagnosed and 50,000 deaths in 2013
(Siegel et al., 2013). Recent studies reported an increased
frequency of colon cancer in adults younger than 50, with
these patients more likely to show an advance stage of the dis-
ease (Bailey et al., 2015). Over 90% of CRCs are adenocarci-
nomas, while rarer forms include neuroendocrine, squamous
cell, spindle cell, and undifferentiated carcinomas (Fleming
et al., 2012).
Colitis-associated colon cancer (CAC) accounts for 1% of
CRC (Yashiro, 2014). The link between chronic inflammation
and increased tumorigenesis has been well documented in in-
flammatory bowel diseases (IBD), including ulcerative colitis
(UC), and Crohn’s disease (CD) (Rogler, 2014; Terzic et al.,
2010). IBDs are associated with increased production of pro-in-
flammatory cytokines, which are associated with the activation
of NF-kB, signal transducer and activator of transcription 3
(STAT3), and mitogen-activated protein kinase (MAPK). Each
of these pathways contributes to tumor progression in CRCs
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Figure 1. Nlrx1 Deficiency Leads to Increased Inflammation and Colitis-Associated Tumorigenesis
(A) In the chronic CAC model, WT and Nlrx1/ mice were challenged with A/D.
(B) The percent weight change after A/D treatment is shown. Each data point is the average from three independent experiments with n indicated.
(C) Cumulative clinical scores were measured at days 7, 26, and 45. Each data point represents one animal.
(D) Photomicrographs show H&E-stained colons from untreated (UT) WT, UT Nlrx1/, A/D-treated WT with mild inflammation (black arrowhead) and crypt
shortening (white arrowhead), and A/D-treated Nlrx1/ with extensive inflammation (black arrowhead), crypt loss and atrophy (white arrowhead) and early
mucosal dysplasia (orange arrowhead). Scale bars represent 50 mm.
(E) Total histology score for UT or A/D-treated WT and Nlrx1/ mice scored in a blinded fashion.
(F) Average epithelial defects were measured from H&E stained colons as indicated. Graph is a compilation of three separate experiments.
(legend continued on next page)
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(Ben-Neriah and Karin, 2011; Dhillon et al., 2007; O’Shea et al.,
2013). NF-kB regulation of CRC development occurs through
the enhanced survival of pre-malignant epithelial cells and
release of inflammatory cytokines, which promote tumor growth
(Ditsworth and Zong, 2004; Greten et al., 2004; Staudt, 2010).
Elevated levels of IL-1b, tumor necrosis factor a (TNF-a), and
interleukin 6 (IL-6) are commonly associated with both IBD and
CRC (Becker et al., 2005; Lin and Karin, 2007; Waldner et al.,
2012). In particular, IL-6 and STAT3 potently stimulate colon can-
cer proliferation and have critical roles in colon tumor develop-
ment in preclinical models (Bollrath et al., 2009; Corvinus et al.,
2005; Grivennikov et al., 2009). There is also a strong correlation
between local IL-6 accumulation and clinical activity of IBD in hu-
mans (Atreya and Neurath, 2005; Hyams et al., 1993).
The initial connection between IBD and the NLR family was
based on the strong genetic association between NOD2/
CARD15 mutations in Crohn’s disease and colon cancer (Hugot
et al., 2001; Kurzawski et al., 2004; Ogura et al., 2001). Mouse
models of CAC have demonstrated that other NLRs, such as
NLRP3, NLRP6, and NLRP12, also protect against CAC (Allen
et al., 2010; Anand et al., 2012; Chen et al., 2011; Dupaul-Chic-
oine et al., 2010; Elinav et al., 2011; Zaki et al., 2010). The NLRP3
and NLRP6 inflammasomes appear to limit CAC primarily
through the induction of IL-18, while NLRP12 reduces NF-kB
and ERK activation, hence reducing chemokines and nitric oxide
that promote tumorigenesis (Allen et al., 2012; Zaki et al., 2011).
NLRX1 does not exhibit inflammasome function and is
uniquely localized to the mitochondria (Moore et al., 2008; Tattoli
et al., 2008). NLRX1 attenuates TRAF6, mitochondrial antiviral
signaling protein (MAVS)/retinoic acid-inducible gene I (RIG-I),
interferon regulatory factor 3 (IRF3), and IkB kinase (IKK)
signaling in response to viral infection and TLR signaling (Allen
et al., 2011; Moore et al., 2008; Xia et al., 2011), but it is also
required for the induction of reactive oxygen species in response
to pathogens (Abdul-Sater et al., 2010; Tattoli et al., 2008). As a
result of its impact on key signaling pathways, NLRX1 negatively
regulates the expression of pro-inflammatory cytokines,
including IL-6 (Allen et al., 2011), a cytokine that has a central
role in CAC and is a target of therapies for the treatment of IBD
(Allocca et al., 2013). A recent study reported that NLRX1
expression is reduced in patients with chronic obstructive
pulmonary disease (COPD), and the absence of NLRX1 exacer-
bated amodel of COPD (Kang et al., 2015). Thus, one of the func-
tions of NLRX1 is to attenuate over-zealous immune responses.
Therefore, elucidating the molecular regulation and function of
NLRX1 in CAC or sporadic CRC has the potential to identify
novel pathways and therapeutic targets for the treatment of
colon cancer.(G) Quantification of macroscopic polyp formation in the colons of WT and Nlrx1
compilation of three separate experiments. nR 4 mice/group.
(H) Serum cytokine levels of IL-6, TNF-a, and IL-1b were measured by ELISA. Va
(I) Expression of Il6, Tnfa, and Il1b transcript in colon homogenates was measured
WT sample (mean ± SEM). Graph is a compilation of three separate experiments
(J) Proteins isolated from distal colonic tissue obtained from UT or A/D-treated W
western blot analysis with indicated protein loading control. Each lane represent
(K) Densitometric measurement of western blots was obtained from three indepen
***p < 0.001, and ****p < 0.0001.
See also Figure S1.
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well reported; however, CAC represents only 1% of CRC. By
contrast, the importance of NLRs in the more prevalent sporadic
colon tumors is sorely lacking. This current study identifies an
important role for Nlrx1 in suppressing tumorigenesis in both
CAC and sporadic colon cancer models by restricting the activa-
tion of NF-kB, MAPK, STAT3, and IL-6 production. In contrast to
most inflammasome NLRs, which function through the myeloid-
monocytic hematopoietic system, NLRX1 exerts its impact
primarily through non-hematopoietic cells such as colon crypt
cells. The importance of NLRX1 in cells other than hematopoietic
is consistent with its role in sporadic CRC modeled after familial
adenomatous polyposis (FAP). FAP is a hereditary disease char-
acterized by the development of colon polyps, attributed to the
deletion of the APC (adenomatous polyposis coli) gene (Fodde
et al., 2001). Mutations in the APC gene also lead to sporadic
colon cancer. The ApcMin/+ mouse model has a point mutation
in the Apc gene, which predisposes the mice to increased spon-
taneous intestinal polyps. This study reveals that compared to
Apcmin/+ controls, Apcmin/+ mice lacking Nlrx1 have a dramati-
cally increased tumor burden accompanied by increased IL-6,
STAT3, b-catenin, and cathepsin B activation. Treatment of
Nlrx1/ApcMin/+ mice with anti-IL6R therapy reduced STAT3
activation, decreased tumor number, and increased survival,
indicating that increased IL-6 is a causative factor in tumorigen-
esis linked to NLRX1-deficiency. Expression analyses of clinical
human colon cancer samples andmeta-analysis of multiple pub-
lic databases revealed that NLRX1 expression is significantly
lowered in CRC when compared to normal colon tissues. These
findings indicate that the loss or reduction of NLRX1 may
contribute to human colon cancers.
RESULTS
Nlrx1/ Mice Are More Susceptible to Chronic
Azoxymethane/Dextran Sodium Sulfate-Induced
Colitis-Associated Colon Cancer
To test the hypothesis that NLRX1 impacts colon tumorigenesis,
Nlrx1/ and wild-type (WT) littermates were subjected to a well-
characterized CAC model that combines the genotoxic DNA-
methylation agent, azoxymethane (AOM), and dextran sodium
sulfate (DSS) (Neufert et al., 2007). CACwas induced by injecting
a single dose of AOM, followed by three cycles of 3% DSS
administration for 5 days followed by 14 days of regular drinking
water, hereafter referred to as A/D treatment (Figure 1A). A/D-
treated Nlrx1/ mice exhibited statistically greater weight loss
than A/D-treated wild-type mice (Figure 1B). A clinical score
based on body condition, stool consistency, rectal bleeding,/mice after A/D treatment. Each data point represents one animal. Graph is a
lues are averages from two independent experiments. nR 6 mice/group.
by qPCR using comparative CT method (2
DDCT) and graphed as fold over UT
.
T and Nlrx1/ mice were analyzed for NF-kB, MAPK, and STAT3 activity by
s one animal.
dent experiments. nR 5mice/group, n.s., non-significant. *p < 0.05, **p < 0.01,
s
and the presence of blood in the stool (Allen et al., 2010) was
significantly higher in Nlrx1/ animals compared to WT controls
(Figure 1C). The histologic appearance of the Nlrx1/ colons
harvested at 55 days post A/D injection showed increased total
histology score (THS) (Figures 1D and 1E), which evaluates
severity and extent of inflammation, epithelial defects, crypt
atrophy, and mucosal dysplasia/neoplasia. Nlrx1/-treated
colons had more widespread epithelial defects compared to
controls as scored in a blinded fashion by a board-certified
veterinarian pathologist (Figure 1F, see the Experimental Proce-
dures for a detailed description).
On day 55 after the start of A/D, colons were harvested and
macroscopic polyps were counted. A/D-treated Nlrx1/ mice
exhibited significantly more polyps in the distal region of their co-
lons compared to A/D-treated WT controls (Figure 1G). Nlrx1/
mice also exhibited greater tumor volume compared to WT con-
trols (Figure S1A). Mice treated with DSS or AOM alone had few,
if any, polyps. Further analysis by endoscopy with a different
group of mice revealed that A/D-treated Nlrx1/ mice devel-
oped more polyps or lesions at the time of examination (day 48
of the A/D treatment course) compared to WT control mice (Fig-
ure S1B). NLRX1 attenuates cytokine expression in fibroblasts
(Allen et al., 2011). To assess if this occurs in CAC, serum from
A/D-treated Nlrx1/ mice were prepared and showed signifi-
cantly higher levels of IL-6, TNF-a, and IL-1b protein than con-
trols as determined by ELISA (Figure 1H) and greater Il6, Tnfa,
and Il1b RNA expression as determined by real-time PCR from
colon tissues (Figure 1I). Previous reports have demonstrated
the role of increased NF-kB and ERK activation in CAC develop-
ment (Greten et al., 2004). Western blot analysis revealed that
colons of chronic DSS- or A/D-treated Nlrx1/mice had higher
levels of phosphorylated IkBa and ERK1/2 compared toWT con-
trols (Figures 1J and 1K). Furthermore, IL-6 induces the activa-
tion of STAT3, which is dysregulated in colon cancer. Colons
from A/D-treated Nlrx1/ mice had significantly higher levels
of phosphorylated STAT3 compared to WT controls (Figures
1J and 1K). These results show that NLRX1 mitigates several
known tumor-promoting signaling pathways during CAC.
Nlrx1 Expression in the Non-hematopoietic
Compartment Mediates Protection against Colon
Tumorigenesis
NLRX1 iswidely expressed in different tissues andorgans (Moore
et al., 2008), hence its impact on CAC might be attributed to its
expression in hematopoietic and/or non-hematopoietic cells. To
address this, the following four groups of bone marrow chimeras
were generated to test whether hematopoietic and/or non-he-
matopoietic cellswereneeded toprotect againstpolyp formation:
(1) irradiated WT mice that received bone marrow fromWT litter-
mates (WT>WT, control group), (2) irradiatedWTcontrolmice that
received bone marrow from Nlrx1/ donors (Nlrx1/>WT,
hematopoietic component was Nlrx1-deficient), (3) irradiated
Nlrx1/ mice that received bone marrow from Nlrx1/ donors
(Nlrx1/>Nlrx1/, Nlrx1/>Nlrx1/, global Nlrx1 deficiency),
and (4) irradiated Nlrx1/ mice that received bone marrow from
WT donors (WT>Nlrx1/, non-hematopoietic compartment
was Nlrx1-deficient). All reconstituted mice were treated with
A/D and monitored for 55 days. Within the first 10–15 daysCellpost A/D treatment, almost 50% of the Nlrx1/>Nlrx1/,
Nlrx1/>Nlrx1/, and WT>Nlrx1/ mice died (Figure 2A). Of
the mice that survived, a clinical score was assessed.
WT>Nlrx1/ and Nlrx1/>Nlrx1/ groups showed increased
clinical scores compared to the WT>WT controls and the
Nlrx1/>WT groups at all three indicated time points (Figure 2B).
WT>Nlrx1/ and Nlrx1/>Nlrx1/ groups had an increase in
THS when compare to Nlrx1/>WT group andWT>WT controls
(Figures2Cand2D).Nlrx1/>Nlrx1/ hadahigher THSpossibly
due to the fact that NRLX1 is expressed in many different cell
types (Figure 2D). Similar to findings with non-chimeric Nlrx1/
mice, theNlrx1/>Nlrx1/grouphadahigher numberof colonic
polyps than WT>WT controls (Figure 2E). WT>Nlrx1/ mice
showed significantly higher numbers of polyps than the WT>WT
and Nlrx1/>WT mice (Figure 2E). Colonic polyp numbers in
Nlrx1/>WT mice were not significantly different from WT>WT
controls. Nlrx1/>Nlrx1/ and WT>Nlrx1/ mice, but not
Nlrx1/>WT mice, had significantly increased tumor volume
compared to WT>WT mice (Figure 2F). Additionally, phosphory-
lated STAT3 was higher in Nlrx1/>Nlrx1/ and WT>Nlrx1/
Nlrx1/>Nlrx1/ and WT>Nlrx1/ mice compared to
Nlrx1/>WTandWT>WTmice (Figure 2G). A composite of three
experiments confirmed these results (Figure 2H). These results
indicate that the presence of Nlrx1 in the non-hematopoietic
compartment is primarily required to limit A/D-induced tumori-
genesis and STAT3 activation.
Loss of Nlrx1 in the Apcmin/+ Model of Sporadic CRC
Leads to Increased Mortality and Tumor Burden
The above data indicate a contribution of Nlrx1-deficiency from
the non-hematopoietic compartment during CAC pathogenesis.
However, the majority of colon cancers are not associated with
CAC. Therefore, we explored the role of NLRX1 in a model of
sporadic colon cancer. APCmutations are found in85% of hu-
man colon cancers or precancerous adenomas, and the loss of
APC in epithelial cells is sufficient to drive intestinal tumorigen-
esis (Kinzler and Vogelstein, 1996; Schwitalla et al., 2013).
Apcmin/+ mice have a germline mutation in the APC gene and
develop spontaneous polyps (Fodde et al., 2001). Usually,
Apcmin/+ mice become moribund within 168 days of age due to
complications from intestinal tumors (Heyer et al., 1999). To
explore the role of NLRX1 in a model of sporadic colon cancer,
Nlrx1/ mice were bred with Apcmin/+ mice to test if the loss
of Nlrx1 affected spontaneous tumor development and lethality.
Survival of Nlrx1/Apcmin/+ mice was dramatically decreased
when compared to Apcmin/+ littermate controls (Figure 3A).
Mice were monitored and harvested at 42, 84, and 168 days of
age to elucidate potential factors of early mortality (Figure S2A).
At 168 days, Nlrx1/Apcmin/+ mice exhibited obvious signs of
hunched back (Figure S2B), which correlated with an increase
in clinical score (Figure 3B). Apcmin/+ and Nlrx1/Apcmin/+
mice did not differ in body weight at 84 to 168 days, although
there was a slight and statistically significant difference between
Nlrx1/ and WT mice at 42 days (Figure S2C). Macroscopic
analysis of unstained colons and colons stained by Alcian blue
revealed thatNlrx1/Apcmin/+ colons had increased polyps (Fig-
ure 3C). The numbers of visible polyps were quantified at three
different time points. At 42 days of age, colonic (Figure 3D) polypReports 14, 2562–2575, March 22, 2016 ª2016 The Authors 2565
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Figure 2. Nlrx1 Expression in the Non-hematopoietic Compartment Is Primarily Required for Protection against AOM/DSS-Induced
Tumorigenesis
Bone-marrow chimeras of WT and Nlrx1/ mice were challenged with AOM and 2.5% DSS (A/D).
(A and B) Mice from two independent experiments were monitored for (A) mortality and (B) clinical score of disease; nR 6 mice/group.
(C) Photomicrographs of H&E-stained colons from A/D-treated WT>WT with mucosal and submucosal inflammation (black arrowheads) and crypt shortening
(white arrowhead); A/D-treated Nlrx1/>WT mice with similar features; A/D-treated Nlrx1/>Nlrx1/ mice with extensive inflammation separating crypts
(black arrowhead), crypt dysplasia (orange arrowhead), and partial penetration of muscularis mucosa (green arrowheads); A/D-treated WT>Nlrx1/ mice with
inflammation (black arrowhead) and a sessile adenoma (bracket) with dysplasia, including crypt infolding and branching and loss of goblet cells and nuclear
polarization (orange arrowheads). Scale bars represent 50 mm.
(D) Total histology score of colons represented in (C).
(E) Macroscopic colonic polyps were counted on day 55 post-A/D treatment. Each data point represents one animal. Graph is the compilation of two independent
experiments.
(F) Average colon tumor volume was measured. nR 6 mice/group.
(G) Proteins isolated from distal portion of colons were analyzed by western blot for STAT3 activation. Each lane represents one animal.
(H) Densitometric measurement of western blots was obtained from three independent experiments. nR 5mice/group, n.s., non-significant. *p < 0.05, **p < 0.01,
***p < 0.001, and ****p < 0.0001.
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Figure 3. Nlrx1 Deficiency Leads to Increased Disease and Polyp Burden in the Apcmin/+ Model and Sporadic CRC
(A) WT, Nlrx1/, Apcmin/+, and Nlrx1/Apcmin/+ mice were followed for 168 days for long-term survival; nR 9 mice/group.
(B) Cumulative clinical score ofWT,Nlrx1/,Apcmin/+, andNlrx1/Apcmin/+ mice at 42, 84, and 168 days Images ofWT,Nlrx1/,Apcmin/+, andNlrx1/Apcmin/+
mice at 84 and 168 days of age.
(C) Polyps in representative colons from mice at 84 (left) and 168 days (right) of age that were either unstained (top) or stained with Alcian blue. Polyps are
highlighted by red circles.
(D and E) Quantification of macroscopic polyp formation and average tumor volume in the colons of WT, Nlrx1/, Apcmin/+, and Nlrx1/Apcmin/+ mice at 42, 84,
and 168 days of age. Each data point represents one animal. nR 5 mice/group, n.s., non-significant. *p < 0.05, **p < 0.01, and ****p < 0.0001.
See also Figure S2.
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numbers were not significantly different among the four groups.
However, at 84 days and 168 days of age, a modest number of
polyps appeared in Apcmin/+ mice as reported in the literature
(Heyer et al., 1999), while Nlrx1/Apcmin/+ mice developed
significantly more visible polyps in their colons compared to
Apcmin/+ mice (Figure 3D). In addition, Nlrx1/Apcmin/+ colons
had larger tumor volume when compared to Apcmin/+ colons
(Figure 3E). These results suggest that NLRX1 attenuates both
polyp number and tumor volume during sporadic colon cancer.
NLRX1 Attenuates Aberrant Cellular Proliferation and
Disease Progression in the APCmin/+ Mouse Tumor
Model
Histological analysis of H&E-stained colons from 168-day-old
Nlrx1/Apcmin/+ mice revealed a higher THS marked by more
severe histologic lesions, including increased incidence of
colonic dysplasia and neoplasm compared to similar-aged
Apcmin/+ or Nlrx1/ mice (Figure 4A, see figure legend for a
detailed description of the histology). We also observed a higher
rate of distal inflammation in the colons of Nlrx1/Apcmin/+ mice
(Figure 4B). In addition, we observed no difference in the per-
centage of cleaved caspase 3, a marker of apoptosis, between
WT and Nlrx1/ (Figure 4C) while we saw significantly higher
levels of Ki67+ cells in the basal end of colon crypts in Nlrx1/
and Nlrx1/Apcmin/+ mice compared to wild-type and Apcmin/+
mice, which is an indicator of increased proliferation (Figures
4D and 4E). APC controls the stability of b-catenin, a key regu-
lator of Wnt signaling, stem cell renewal, cell fate, and growth
(Clevers and Nusse, 2012). Additionally, increased cytoplasmic
b-catenin is a marker of carcinogenesis (Fodde et al., 2001).
Immunohistochemical staining of Nlrx1/Apcmin/+ tumors
showed increased b-catenin compared to Apcmin/+ controls
(Figure 4F).
Our findings indicate that STAT3 was hyperactivated in the
absence of NLRX1 (Figure 1J). STAT3 is known to activate
cathepsin-B, which is involved in the oncogenesis and metas-
tasis of human cancers and it is upregulated in dysplastic ade-
nomas and colorectal carcinoma (Ding et al., 2014; Kuester
et al., 2008). Ex vivo imaging of colons of Nlrx1/ApcMin/+
mice, ApcMin/+, Nlrx1/, and WT controls injected with a
cathepsin B-inducible fluorescence probe (Prosense 680) (Ding
et al., 2014; Gounaris et al., 2013) revealed significantly higher
fluorescence in colons of Nlrx1/ApcMin/+ versus ApcMin/+
mice, which is indicative of increased cathepsin B activity in
the Nlrx1/ApcMin/+ mice (Figure 4G). Colons of Nlrx1/ and
WT littermates showed minimal cathepsin B signals (Figure 4G).
This result indicates that cathepsin B activity is enhanced in
Nlrx1/ApcMin/+mice.
NLRX1 Attenuates Tumor-Promoting Signaling
Pathways in Colon Crypts during the Apcmin/+ Model of
Spontaneous CRC
To assess whether the presence of NLRX1 attenuated key tu-
mor-promoting pathways in the Apcmin/+ model, colons were
isolated and analyzed by western blot. Nlrx1/Apcmin/+ colons
had higher levels of phosphorylated p65, IkBa, JNK1/2, and
ERK1/2 at 84 (Figure 5A) and 168 (Figure 5B) days of age
compared to Nlrx1/, Apcmin/+, and WT mice. Phosphorylated2568 Cell Reports 14, 2562–2575, March 22, 2016 ª2016 The AuthorSTAT3 was also elevated in Nlrx1/Apcmin/+ colons (Figures
5A and 5B). Since Nlrx1/Apcmin/+ had increased levels of
Ki67+ in their colon crypt (Figure 4D), we isolated these cells to
determine the impact of NLRX1-deficiency. These cells were
EpCAMhi and CD45lo (Figure S3). Nlrx1/Apcmin/+ colon crypts
from 84-day-old mice had higher levels of phosphorylated p65,
ERK1/2, and STAT3 (Figure 5C) than controls. Since STAT3
can be activated by the key tumor-promoting cytokine, IL-6, Il6
transcript was measured by qPCR, and it was significantly
increased in Nlrx1/Apcmin/+ colons (Figure 5D). In contrast,
levels of Tnfa and Il1b were not significantly different between
Apcmin/+ andNlrx1/Apcmin/+ colons (Figure 5D). ELISA analysis
verified significantly higher levels of IL-6 protein produced by
colonic samples isolated from Nlrx1/Apcmin/+ animals
compared to Apcmin/+ mice, but no difference in IL-1b and
TNF-a, which was below detection (Figure 5E). Taken together,
these results indicate that the loss of NLRX1-activated multiple
pathways that contribute to tumor development or progression.
Anti-IL6R Therapy Significantly Decreases Tumor
Burden and STAT3 Activity in the Nlrx1/Apcmin/+
Animals
To assess whether the pathways delineated above contributed
to the mechanism by which NLRX1 suppressed tumor growth,
we directly assessed the role of elevated IL-6 in
Nlrx1/Apcmin/+ animals with antibodies against IL-6 receptor.
WT, Nlrx1/, Apcmin/+, and Nlrx1/Apcmin/+ animals were in-
jected with 20 mg/ml of anti-IL6R per mouse biweekly for
10 weeks. Cumulative clinical score revealed that
Nlrx1/Apcmin/+ mice on anti-IL6R treatment had a significantly
lowered clinical score compared to the untreated (UT)
Nlrx1/Apcmin/+ group (Figure 6A). Anti-IL6R-treated
Nlrx1/Apcmin/+ mice showed significant weight gain compared
to UT controls, while anti-IL6R-treated WT, Nlrx1/, and
Apcmin/+showed a modest, but insignificant weight loss
compared to their UT controls (Figure 6B). After 10 weeks of
anti-IL-6R therapy, colons were harvested and macroscopic
polyps were counted. Anti-IL6R-treated Nlrx1/Apcmin/+ ani-
mals exhibited significantly less polyps in the distal region of their
colons in comparison to UT Nlrx1/Apcmin/+ (Figures 6C and
6D). Western blot showed a significant decrease of phosphory-
lated STAT3 in anti-IL6R-treated Nlrx1/Apcmin/+ animals in
comparison to UT animals (Figure 6E). STAT3 is well docu-
mented to regulate the initial events of tumor development, pro-
gression, and invasiveness (Waldner et al., 2012) (Figure 6F) and
decreased levels of phosphorylated STAT3 observed in anti-
IL6R-treated Nlrx1/Apcmin/+ animals correlated positively
with decreased polyp numbers (Figures 6D and 6F). Thus, these
results indicate that increased IL-6 found in Nlrx1/Apcmin/+
played a causative role in increased polyp formation and height-
ened STAT3 activation.
NLRX1 Expression Is Reduced in Colorectal Cancer
Based on Analysis of the Oncomine Platform and Newly
Isolated Clinical Samples
To examine the relevance of the data in preclinical models to hu-
man colon cancer, the levels of NLRX1 expression in human
CRC was subjected to bioinformatics mining using thes
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Figure 4. Nlrx1 Deficiency on the Apcmin/+ Background Leads to Increased Proliferation and Greater Expression of the Tumor Biomarkers
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(A) Photomicrographs of H&E-stained colons from WT, Nlrx1/, Apcmin/+ mice displayed a pedunculated adenoma (bracket) with mucosal dysplasia, and
Nlrx1/Apcmin/+ colons depicted an area of mucosal dysplasia within an adenoma. Scale bars represent 50 mm.
(B) Total Histology score and distal colon inflammation were determined in H&E-stained colon sections represented in A. All slides were scored in a blinded
fashion.
(legend continued on next page)
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Figure 5. Nlrx1 Deficiency Contributes to
Exacerbated NF-kB,MAPK, and STAT3 Acti-
vation and IL-6 Production in the Apcmin/+
Model
(A–C) Protein lysates were isolated from distal
colon tissues obtained from WT, Nlrx1/,
Apcmin/+, and Nlrx1/Apcmin/+ mice at days 84 (A)
and 168 (B), and isolated colon crypts from 84 days
(C). Lysates were analyzed by western blot for
NF-kB, MAPK, and STAT3 activation. Each lane
represents one animal; nR 3 mice/group.
(D) RNA was isolated from age-matched WT,
Nlrx1/, Apcmin/+, and Nlrx1/Apcmin/+ distal
colonic tissues and analyzed by qPCR for
expression levels of Il6, Tnfa, and Ilb, n R 3
mice/group.
(E) IL-6, TNF-a, and IL-1b proteins produced by
colon explants were analyzed by ELISA, n R 3
mice/group. n.s., non-significant. *p < 0.05, ***p <
0.001, and ****p < 0.0001.
See also Figure S3.Oncomine Platform database. This was followed by an examina-
tion of newly isolated clinical samples from a Chinese Cohort.
Oncomine Platform is an online assembly of microarrays. We
analyzed five databases (listed in the Experimental Procedures)
that contained information regardingNLRX1 expression. We first
analyzed the Cancer Genome Atlas (TCGA) database, which is
the most comprehensive set containing 215 patient and 22 con-
trol samples (Cancer Genome Atlas, 2012). This database
showed that the expression of NLRX1 transcript was signifi-
cantly decreased in colorectal cancer (Figure 7A). Next, we eval-
uated the expression levels of NLRX1 transcript at various(C–E) Quantification of positive cleaved caspase-3 (C) or Ki-67 (D) cells stained per half-length of crypt
Nlrx1/Apcmin/+ mice at 168 days of age shown in (E) for Ki-67. nR 4mice/group, n.s., non-significant. *p < 0.
bars represent 100 mm.
(F) Representative histological micrographs of Apcmin/+ and Nlrx1/Apcmin/+ colon tumors at 168 days s
mice/group. Scale bars represent 50 mm.
(G) Representative images of colons from WT, Nlrx1/, Apcmin/+, and Nlrx1/Apcmin/+ mice at 168 days of
scale shown to right) due to active cathepsin B cleavage of target probe were visualized by fluorescence re
2570 Cell Reports 14, 2562–2575, March 22, 2016 ª2016 The Authorsstages of cancer progression using the
TCGA database (Figure 7B). CRC cases
were staged according to the staging sys-
tem determined by the American Joint
Committee on Cancer (AJCC) and also
known as the tumor-node-metastasis
(TNM) system. In stage I, the tumor has
spread beyond the inner lining of the co-
lon to the second and third layers of the
colon. In stage II, the tumor has spread
to the muscle wall of the colon. In stage
III, the cancer has metastasized to lymph
nodes. In stage IV, the cancer has metas-
tasized to secondary areas of the body
such as the liver or lung. This analysis
shows that NLRX1 expression was signif-
icantly higher in healthy controls versus allfour CRC stages (Figure 7B). Next, we confirmed these findings
using four smaller databases within the Oncomine Platform.
Significantly lower expression of NLRX1 was detected in CRC
samples in all four databases (Figure 7C). Thus, the composite
data from five public databases support the conclusion that
NLRX1 expression is statistically lower in CRC than in healthy
colons.
Public database typically do not provide detailed information
regarding the patients. Thus, we analyzed mRNA isolated from
40 formalin-fixed and paraffin-embedded (FFPE) CRC samples
plus 40 adjacent normal tissues obtained from a Chinese patientwas determined from age-matched Apcmin/+ and
05 **p < 0.01, ***p < 0.001, and ****p < 0.0001. Scale
tained with b-catenin are shown (arrows), n R 3
age are shown. Fluorescent signals (with intensity
flectance imaging. nR 2 mice/group.
A B
C
D E
F
Figure 6. Inhibition of IL-6 Signaling in Nlrx1/Apcmin/+ Mice Reduces Mortality and Tumorigenesis by Decreasing STAT3 Activation
(A) WT, Nlrx1/, Apcmin/+, and Nlrx1/Apcmin/+ animals were subjected to anti-IL6R administration at 20 mg/ml/animal. Cumulative clinical score of animals on
and off treatment were monitored. nR 4 mice/group.
(B) The percent weight change for animals that were untreated (UT) or given 10 weeks of anti-IL6R therapy is shown for each strain. nR 4 mice/group.
(C) Images are shown of colons isolated at 10 weeks after anti-IL6R therapy from WT, Nlrx1/, Apcmin/+, and Nlrx1/Apcmin/+ animals with polyps indicated
(arrows).
(D) Quantification of macroscopic polyp formation in the colons of UT or anti-IL6R-treated animals as indicated. Each data point represents one animal. nR 4
mice/group, n.s., non-significant. *p < 0.05 **p < 0.01, ***p < 0.001, and ****p < 0.0001.
(legend continued on next page)
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cohort for the expression of NLRX1. The patients selected had
not received any chemotherapy or radiotherapy prior to colonic
resection. In agreement with Figure 7A, NLRX1 transcripts
were significantly reduced within the CRC samples relative to
healthy tissues (Figure 7D). The combined data collected from
multiple public databases and an additional cohort of human
clinical samples provides overwhelming clinical evidence that
NLRX1 gene expression is reduced in human CRC in compari-
son to healthy colons, further indicating a critical role for
NLRX1 in limiting CRC.
DISCUSSION
The link between cancer and a number of key signaling pathways
is well established (Coussens and Werb, 2002). Elevated NF-kB
signaling can de-differentiate intestinal epithelial cells that even-
tually acquire stem-like properties and tumor-initiating capacity
(Shaked et al., 2012). NF-kB also facilitates Wnt-driven prolifer-
ation of intestinal stem cells, which leads to CRC (Myant et al.,
2013; Schwitalla et al., 2013). MAPK regulates intestinal cell pro-
liferation and epithelial differentiation and promotes progression
and oncogenesis of human CRC (Dhillon et al., 2007; Lee et al.,
2010; Taupin and Podolsky, 1999). NF-kB and STAT3 coopera-
tively regulate a number of target genes regulating cell cycle and
proliferation (Lee et al., 2009; Yang et al., 2007). This work shows
that NLRX1 serves as a checkpoint of these multiple critical can-
cer-promoting pathways to maintain a homeostatic, noncan-
cerous state.
A previous study of NLRX1 in a model that used AOM alone,
which is not known to strongly induce tumorigenesis, and a
model that involved a short course (3-day) of AOM-DSS treat-
ment, which is unlikely to induce full tumorigenesis, has resulted
in conflicting findings regarding the role of NLRX1 (Soares et al.,
2014). In contrast, the current study is distinguished by several
unique features. First, NLRX1 uniformly suppressed colon
tumorigenesis in both CAC and sporadic colon cancer models.
Second, the loss of Nlrx1 expression led to heightened IL-6 pro-
duction and activated STAT3, which are key regulatory
pathways in colon cancer that have not been connected to
NLR function in tumors. Enhanced NF-kB and ERK activity are
known to enhance levels of IL-6, which can lead to STAT3 acti-
vation resulting in increased oncogenesis (Corvinus et al.,
2005). Cross talk between STAT3 and b-catenin have been
documented in different cancers (Armanious et al., 2010;
Ibrahem et al., 2014), and STAT3 can also enhance cathepsin B
(Dauer et al., 2005), which enhances cancer progression and cell
proliferation. Since cathepsin B and b-catenin activity are height-
ened in Nlrx1/Apcmin/+ mice, inhibitors of these two proteins
may be useful in targeting human CRCs with low NLRX1 expres-
sion. Third, while other NLRs such as NLRP3 exert their impact
primarily through the hematopoietic compartment, NLRX1
exerts its impact on tumorigenesis mostly via the non-hemato-
poietic compartment such as colon crypts. Fourth, anti-IL6R(E) Protein lysates were isolated from distal colon tissues obtained fromWT,Nlrx1
with anti-IL6R for 10 weeks. Lysates were analyzed by western blot for phospho
(F) Model of NLRX1 negatively impacting NF-kB and MAPK, which increase IL-6
pathways to increase proliferation in tumors.
2572 Cell Reports 14, 2562–2575, March 22, 2016 ª2016 The Authortherapy effectively decreased tumorigenesis and STAT3 activa-
tion in Nlrx1/Apcmin/+ animals. Finally, NLRX1 is also reduced
in multiple human CRC patient cohorts, which confers transla-
tional relevance to these findings and supports the concept
that NLRX1 may serve as a checkpoint against human colon
cancer. The discovery of reduced NLRX1 in human CRC further
suggests that NLRX1 expression may be used as a biomarker of
CAC or CRC (Thorsteinsdottir et al., 2011). This finding also has
implications for personalized therapy. For example, inhibitors of
STAT3 or IL-6, which are Food and Drug Administration (FDA)-
approved for other diseases, might be repurposed for controlling
human CRCs that have low NLRX1 expression. Based on the
findings in this and previous reports, a working model of how
NLRX1 affects tumorigenesis is shown in Figure 6F.
In summary, this report finds that the presence of NLRX1 limits
activation of key signaling pathways leading to NF-kB, MAPK,
IL-6, and STAT3 activation, which promote various aspects of
tumor development. The loss of NLRX1 creates a microenviron-
ment that potentiates the development of tumors in both colitis-
associated and sporadic models of CRC. A possible impact is
that NLRX1 affects tumor-promoting signals via changes in the
microbiome, which would be an important future investigation.
EXPERIMENTAL PROCEDURES
Animals
All studies were conducted in accordance with IACUC guidelines of the Uni-
versity of North Carolina (UNC) at Chapel Hill and NIH guide for the Care
and Use of Laboratory Animals. All experiments were performed under SPF
conditions using either 6- or 8-week-old male mice or with age as indicated.
C57BL/6 (wild-type mice) and Apcmin/+ mice originated from Jackson Labora-
tories and were maintained at UNC Chapel Hill for more than nine generations.
Nlrx1/ mice on the C57BL/6 background have been described previously
(Moore et al., 2008). Nlrx1/ mice were crossed with Apcmin/+ mice to
generate Nlrx1/Apcmin/+ mice. Littermates were used as indicated. See
the Supplemental Experimental Procedures for colitis and colon cancer
models, generation of radiation bone marrow chimeras, and assessment of
colon polyps and histopathology.
Assays
Isolation of RNA, tissue extracts, and soluble protein and biochemical and
molecular analyses and molecular imaging of proteases are described in the
Supplemental Experimental Procedures.
Bioinformatics and Experimental Analysis of NLRX1 Expression in
Human CRC
Microarray studies from the Oncomine Platform containing data describing
NLRX1 expression in CRC and the collection and processing of human CRC
specimens are described in the Supplemental Experimental Procedures.
Statistics
All results are presented as the mean ± SEM. Significance between two
groups was assessed by the Student’s two-tailed t test. Datasets that had
more than two sets of data for analysis were analyzed by ANOVA with Tu-
key–Kramer HSD post test for multiple comparisons to determine signifi-
cance. The product limit method of Kaplan-Meier was utilized for generating
the survival curves, which were compared using the log rank test. See the/,Apcmin/+, andNlrx1/Apcmin/+ mice that were either left UT or were treated
rylated STAT3. Each band represents one animal; nR 3 mice/group.
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Figure 7. NLRX1 Expression Is Reduced in
Multiple Colorectal Cancer Patient Data-
bases and in Clinical Samples
(A) CRC microarray databases were mined for
NLRX1 expression. The raw data were exported
from the TCGA CRC database, with representa-
tions of 22 healthy control and 215 CRC samples.
Mean ± SEM, presented as Log2 median-centered
ratio expression. Unpaired Mann-Whitney test was
used to evaluate the statistical significance.
(B) Correlation analysis compared expression
levels of NLRX1 among different stages of CRC
progression. TNM stage information was exported
from the TCGA colon database.
(C) Reduced NLRX1 expression was found in four
additional CRC databases. Log2 median-centered
ratio expression is presented for the four datasets
used. Box plots were generated by GraphPad,
whiskers are drawn down to the 10th percentile and
up to the 90th percentile. Points below and above
the whiskers are drawn as individual dots.
(D) NLRX1 expression in human clinical CRC FFPE
samples collected from a Chinese patient cohort
(n = 40) was analyzed by qPCR using comparative
CT method (2
DDCT) (mean ± SEM). **p < 0.01,
***p < 0.001, and ****p < 0.0001.
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Supplemental Experimental Procedures for statistics used with clinical hu-
man samples.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and three figures and can be found with this article online at http://dx.doi.
org/10.1016/j.celrep.2016.02.064.
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